| Literature DB >> 26703953 |
Samuel Thomas1, Ling Hao2, William A Ricke1,3, Lingjun Li1,2,4.
Abstract
Urinary proteomics has become one of the most attractive topics in disease biomarker discovery. MS-based proteomic analysis has advanced continuously and emerged as a prominent tool in the field of clinical bioanalysis. However, only few protein biomarkers have made their way to validation and clinical practice. Biomarker discovery is challenged by many clinical and analytical factors including, but not limited to, the complexity of urine and the wide dynamic range of endogenous proteins in the sample. This article highlights promising technologies and strategies in the MS-based biomarker discovery process, including study design, sample preparation, protein quantification, instrumental platforms, and bioinformatics. Different proteomics approaches are discussed, and progresses in maximizing urinary proteome coverage and standardization are emphasized in this review. MS-based urinary proteomics has great potential in the development of noninvasive diagnostic assays in the future, which will require collaborative efforts between analytical scientists, systems biologists, and clinicians.Entities:
Keywords: Biomarker; Mass spectrometry; Proteomics; Urine
Mesh:
Substances:
Year: 2016 PMID: 26703953 PMCID: PMC4888976 DOI: 10.1002/prca.201500102
Source DB: PubMed Journal: Proteomics Clin Appl ISSN: 1862-8346 Impact factor: 3.494